Osimertinib is a third-generation, oral EGFR TKI specifically designed to target both sensitizing EGFR mutations (e.g., exon 19 deletions and L858R) and the T790M resistance mutation that often emerges after first-line EGFR TKI therapy in non-small cell lung cancer (NSCLC).77 Unlike earlier-generation EGFR inhibitors, osimertinib binds irreversibly to the mutant receptor via covalent interaction, offering enhanced potency and selectivity while sparing wild-type EGFR to reduce off-target toxicity. Here, EGFR is linked to non-small cell lung carcinoma.